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ABSTRACT
Introduction Parkinson’s disease (PD) is a common 
neurodegenerative disorder with substantial morbidity. 
No disease- modifying treatments currently exist. The 
glucagon like peptide-1 receptor agonist exenatide has 
been associated in single- centre studies with reduced 
motor deterioration over 1 year. The aim of this multicentre 
UK trial is to confirm whether these previous positive 
results are maintained in a larger number of participants 
over 2 years and if effects accumulate with prolonged drug 
exposure.
Methods and analysis This is a phase 3, multicentre, 
double- blind, randomised, placebo- controlled trial of 
exenatide at a dose of 2 mg weekly in 200 participants 
with mild to moderate PD. Treatment duration is 96 weeks. 
Randomisation is 1:1, drug to placebo. Assessments are 
performed at baseline, week 12, 24, 36, 48, 60, 72, 84 and 
96 weeks.
The primary outcome is the comparison of Movement 
Disorders Society Unified Parkinson’s Disease Rating 
Scale part 3 motor subscore in the practically defined 
OFF medication state at 96 weeks between participants 
according to treatment allocation. Secondary outcomes 
will compare the change between groups among other 
motor, non- motor and cognitive scores. The primary 
outcome will be reported using descriptive statistics and 
comparisons between treatment groups using a mixed 
model, adjusting for baseline scores. Secondary outcomes 
will be summarised between treatment groups using 
summary statistics and appropriate statistical tests to 
assess for significant differences.
Ethics and dissemination This trial has been approved 
by the South Central- Berkshire Research Ethics 
Committee and the Health Research Authority. Results 
will be disseminated in peer- reviewed journals, presented 
at scientific meetings and to patients in lay- summary 
format.
Trial registration numbers NCT04232969, 
ISRCTN14552789.
INTRODUCTION
Parkinson’s disease (PD) is the second 
most common neurodegenerative disease 
affecting over 10 million people worldwide 
and its prevalence is increasing.1 Symptom-
atic treatments are available and mainly focus 
on dopamine replacement strategies.2 3 Such 
therapies provide improvements in the core 
motor features of PD: tremor, limb rigidity 
and slowness of movement (bradykinesia).4 
These symptomatic treatments do not impact 
Strengths and limitations of this study
 ► This is the protocol for the first phase 3 double- blind, 
randomised, placebo controlled trial of exenatide in 
Parkinson’s disease.
 ► This study uses novel secondary outcome measures 
in substudies (cerebrospinal fluid analysis, dopa-
mine transporter imaging and digital technology 
measurement devices) which should provide a more 
sensitive and comprehensive assessment of poten-
tial disease modification.
 ► Although the 2- year follow- up period should provide 
a more definitive signal on disease modification, this 
will take longer to report findings and has risks for 
long- term patient retention.
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on the progressive nature of the disease nor the majority 
of the non- motor symptoms (NMS). Moreover, with time, 
some patients will develop dopamine- refractory gait and 
balance problems leading to falls and risk of fractures; 
speech and swallowing problems leading to difficulty in 
communication and aspiration pneumonia, cognitive 
impairment, visual hallucinations and dementia with 
mounting care needs.3 4 These complications result in 
increased dependence, caregiver strain, need for 24 hours 
care and death. Therefore, PD is a growing problem for 
individuals, healthcare and society making the develop-
ment of disease modifying treatments imperative.
Exenatide (exendin-4) is a licensed and effective treat-
ment for patients with type 2 diabetes mellitus (T2DM).5 
It is an agonist for the glucagon- like peptide 1 (GLP-1) 
receptor and in the presence of elevated blood glucose 
stimulates insulin release. It also increases pancreatic beta 
islet cell mass and reduces apoptosis. Exenatide has been 
the subject of multiple phase 3 trials in patients with type 
2 diabetes and was granted a license for the treatment of 
type 2 diabetes in 2006.5
In parallel with the confirmation of the beneficial 
effects of exenatide on glucose control, laboratory work 
has showed that exenatide has beneficial effects on 
neurons in vitro.6 Exenatide induces neurite outgrowth, 
promotes neuronal differentiation and rescues degen-
erating neuronal cells while also reversing neurotoxin 
induced damage in animal models.6 7 These neurotrophic 
properties have sparked interest regarding its potential 
use as a neurodegenerative disease- modifying agent.8 9
The specific relevance of exenatide to PD has also 
been extensively evaluated. Exenatide has been shown to 
increase transcription of tyrosine hydroxylase (the rate 
limiting enzyme in dopamine synthesis) in brainstem 
catecholaminergic neurons.10 Furthermore, stimulation 
of GLP-1 receptors may have beneficial effects on the 
neurodegenerative processes of PD through downstream 
cellular pathways.6 11 These findings are further supported 
by a recent study suggesting a reduced future risk of devel-
oping PD in T2DM patients treated with GLP-1 agents.12
To investigate the potential effects of exenatide in 
patients with PD, an investigator- initiated pilot trial 
was undertaken.13 This open- label, parallel group, 
randomised controlled trial evaluated the tolerability of 
exenatide (Byetta 10 μg two times per day) in 45 patients 
with moderately severe PD (Hoehn and Yahr stage of 
less than 2.5) over an exposure period of 48 weeks with 
a subsequent washout period of 12 weeks. This showed 
an advantage of 4.9 points in in the Movement Disor-
ders Society Unified Parkinson’s Disease Rating Scale 
(MDS- UPDRS) part 3 (motor subscore) in exenatide 
treated patients at 12 months which persisted even after a 
12- week washout period. Clinically important differences 
in cognition were also noted. Serial DaTscan (Ioflupane 
I 123 injection) imaging showed no progression between 
baseline and 48 weeks in the exenatide treated patients.13
A further phase 2 double blind randomised controlled 
trial evaluating the effects of exenatide in 60 patients 
with PD has subsequently been performed.14 Patients 
were randomised to self- injection of a long acting form 
of exenatide, (Bydureon 2 mg) once weekly, or matched 
placebo for 48 weeks. Detailed assessments every 12 weeks 
for the duration of the treatment and a further assess-
ment at the 60 weeks time point to explore any lasting 
effects following washout of the trial medication were 
performed. Patients receiving exenatide had a mean 3.5 
point advantage in their MDS- UPDRS part 3 OFF medica-
tion scores compared with patients receiving placebo at 
the 60 weeks time point. Biological specimens collected 
from trial participants confirmed changes according to 
treatment with exenatide in downstream cellular effector 
pathways.15
The current trial objective (box 1) is to confirm or 
refute whether the previous positive results can be repro-
duced in a multicentre trial design, including a larger 
Box 1 Trial objectives
Primary
 ► Compare the effectiveness of exenatide once weekly versus place-
bo on the Movement Disorders Society Unified Parkinson’s Disease 
Rating Scale (MDS- UPDRS) part 3 motor subscore in the ‘practically 
defined OFF medication state’ in patients with Parkinson’s disease 
(PD) (change in the MDS- UPDRS part 3 score reflects accumulation 
of motor deficit and therefore is a measure of PD motor progression).
Secondary
 ► Compare differences at 48 and 96 weeks between the exenatide 
and placebo trial arms in:
 – MDS- UPDRS part 1, 2, 3 and 4 ON medication scores.
 – Timed walk assessment ON and OFF medication.
 – Montreal Cognitive Assessment.
 – Safety and tolerability of exenatide as indicated by changes in 
vital signs, weight, clinical laboratory measures and adverse 
events
 – Patient Health Questionnaire.
 – Unified Dyskinesia Rating Scale.
 – Parkinson’s Disease 39 item Quality of Life questionnaire.
 – Levodopa equivalent dose change.
 – A 3- day Hauser diary of PD state (Time- On, Off, Non troublesome 
Dyskinesia, Troublesome dyskinesia, Asleep).
 ► Compare differences in total values over 96 weeks between the ex-
enatide and placebo trial arms in:
 – Health and social care resource use on the modified Client 
Service Receipt Inventory.
 – Health and social care costs.
 – Paid and unpaid carer costs.
 – Quality- adjusted life- years calculated using the EQ- 5D- 5L tariff 
adjusting for baseline.
 ► Compare differences between scores at 48 and 96 weeks between 
the exenatide and placebo trial arms in:
 – MDS- UPDRS part 3 Motor subsection OFF medication score.
Exploratory
Compare differences between slopes at prespecified periods between 
exenatide and placebo trial arms for key outcomes to investigate 
whether exenatide can be considered disease modifying.
EQ- 5D- 5L, EuroQol- 5 Dimension, 5 Level.
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number of participants evaluated over twice as long a 
period as previously. An important secondary objective is 
to explore if positive effects seen after 48 weeks of exen-
atide exposure remain static or increase in amplitude by 
the 96 weeks time point. The hypothesis is that exenatide 
will be associated with reduced MDS- UPDRS part 3 scores 
at the 96- week time point. The overriding priority for 
this trial is to provide evidence to support or refute any 
signal of efficacy of exenatide in PD, and thus provide 
the justification for rapid further investment in this drug 
if appropriate. In parallel with this, is the aim to explore 
whether any biological effect(s) of exenatide, relevant to 
PD, are purely symptomatic effects as opposed to disease- 
modifying effects.
METHODS
This trial protocol was designed using the University 
College London (UCL) Comprehensive Clinical Trials 
Unit (CCTU) Protocol template. The trial is sponsored 
by UCL and coordinated by the CCTU. The protocol was 
designed to provide information about procedures for 
entering participants into the trial, and sufficient detail 
to enable: an understanding of the background, ratio-
nale, objectives, trial population, intervention, methods, 
statistical analyses, ethical considerations, dissemination 
plans and administration of the trial; replication of key 
aspects of trial methods and conduct; and appraisal of the 
trial’s scientific and ethical rigour from the time of ethics 
approval through to dissemination of the results. All stake 
holders (research team, sponsor, CCTU and oversight 
committees) were involved in the design and approval of 
the protocol. A particular emphasis was given to patient 
input in the trial design. This patient and public involve-
ment (PPI) approach has proven to be of value in other 
studies16 and was harnessed to improve the overall study 
design. A focus group meeting with patients was organ-
ised in the protocol design stages to obtain feedback 
from patients which led to a number of amendments 
prior to submission, including the maximum overall trial 
duration of 96 weeks, and the use of OFF- medication 
assessments. Two PPI representatives will serve on the 
trial steering committee (TSC) and will continue to 
provide regular input throughout recruitment. Patients 
will also be provided access to the trial website and a link 
to the protocol and patient information sheets (PIS) on 
request and will be given the opportunity to continue to 
provide comments and contact researchers to further 
discuss their input. The INCLUDE guidance17 is an 
National Institute for Health Research- led initiative to 
improve inclusion of under- served groups. The design of 
the trial is mindful of the value of the steps outlined in 
this initiative and aims to incorporate its recommenda-
tions into overall trial recruitment with the overarching 
aim of providing better access and quality care to under-
served patient groups.
Patient and public involvement
In the development of this protocol, a formal meeting 
hosted by the Cure Parkinson’s Trust was held with six 
patients with PD to obtain patient feedback on the overall 
trial design and logistical aspects of the trial that could 
potentially impede recruitment and retention. The 
aims and objectives of the trial were discussed including 
the importance of distinguishing between symptom-
atic and disease modifying effects of exenatide. Patient 
feedback was clear that a 2- year period would be the 
maximal acceptable duration of self- administration of 
placebo, therefore, the trial duration was reduced from 
the original planned 3- year duration to 96 weeks. The 
use of weekly self- administered injections, and atten-
dance in the off- medication state to assess PD severity 
was discussed in detail and considered acceptable. The 
recruitment strategy has used the patient networks of the 
Cure Parkinson’s Trust and Parkinson’s UK to increase 
the awareness of the trial. Patients and patient represen-
tatives are included in the TSC. At the end of the study, all 
participants will be notified of their randomisation allo-
cation and of the main study results. The results will be 
presented at meetings convened for patient groups and 
published in open access peer reviewed publications.
Trial design
This is a simple parallel group multicentre phase 3, 
double- blind, randomised, placebo- controlled trial which 
includes a 96- week exposure period. Detailed evaluations 
of all participants will take place at screening, baseline, 
24, 48, 72 and 96 weeks (figure 1). Participants will also 
attend on a 12 weekly basis to collect supplies of Inves-
tigational Medicinal Product (IMP). Participants will be 
randomly allocated to receive either exenatide extended 
release 2 mg subcutaneous injection (Bydureon) once 
weekly for 96 weeks n=100, or exenatide extended release 
placebo subcutaneous injection once weekly for 96 weeks 
n=100. In addition, participants will be randomised using 
a minimisation algorithm (with a random element incor-
porated) balancing by research site, participants with 
greater (Hoehn and Yahr stage 2.5) or lesser (Hoehn and 
Yahr stage 2.0 or less) PD severity (in the ON medication 
state), and participation in the substudies (remote moni-
toring, imaging or not participating).
Participants and recruitment
Patients are eligible for screening if they have a clinical 
diagnosis of PD. The Queen Square brain bank criteria18 
can be also be used to validate the diagnosis and ensure 
consistency of diagnosis between sites, however, this is not 
a formal inclusion criterion. The relevance of a positive 
family history of PD, or a confirmed genetic basis for an 
individual’s symptoms will be evaluated in the context of 
other clinical features in determining diagnosis and eligi-
bility. Key inclusion and exclusion criteria are summarised 
in box 2.
In a post hoc analysis of the Exenatide PD phase 2 trial, 
younger patients with shorter disease duration had the 
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best outcomes.19 While aware of this, we feel it is important 
to collect evidence to determine whether exenatide has 
beneficial effects on cognition and axial features of PD, 
and thus took the decision to keep the inclusion criteria 
broad to improve our chances of detecting effects on these 
other outcomes and also ensuring that the results will be 
applicable to the broadest population of PD patients.
Participants will typically be recruited through specialist 
movement disorders clinics at trial sites. The trial will 
be advertised online by the Parkinson’s UK website, the 
Cure Parkinson’s Trust and the NIHR Clinical Research 
Network websites and will be registered on  Clinical-
Trials. gov and the ISRCTN registry. Trial advertisements 
will direct participants to contact teams in order to be 
provided with a PIS and a reply slip to confirm ongoing 
interest and to organise a prescreening telephone call to 
discuss eligibility and suitability for the study. It is antic-
ipated that recruitment will be completed from six UK 
sites (National Hospital for Neurology and Neurosur-
gery (Queen Square, London), King’s College Hospital 
National Health Service (NHS) Foundation Trust 
(London), Oxford University Hospitals NHS Foundation 
Trust (Oxford), Derriford University Hospital (Plym-
outh), Salford Royal Hospital (Manchester) and Western 
General Hospital & Royal Infirmary of Edinburgh 
Figure 1 Outline of trial design.
Box 2 Key inclusion and exclusion criteria for study
Key inclusion criteria
 ► Diagnosis of Parkinson’s disease (PD) based on review of the par-
ticipant’s clinical history, examination findings and response to PD 
medications. The Queen Square brain bank criteria18 can be also be 
used to assist the diagnosis, however this is not a formal inclusion 
criterion. The relevance of a positive family history of PD, or a con-
firmed genetic basis for an individual’s symptoms will be evaluated 
in the context of other clinical features in determining diagnosis and 
eligibility.
 ► Hoehn and Yahr stage ≤2.5 in the ON medication state. This implies 
that all patients will be mobile without assistance during their best 
‘ON’ medication periods.
 ► Between 25 and 80 years of age.
 ► On dopaminergic treatment for at least 4 weeks before enrolment. 
All participants must have had previous or ongoing exposure to do-
paminergic treatment either as L- dopa or a dopamine agonist. If 
L- dopa has been stopped due to side effects or lack of response, 
the local PI should further confirm that the participant has clinical 
symptoms and signs and/or radiological investigations consistent 
with a diagnosis of PD.
 ► Ability to self- administer, or to arrange carer administration of trial 
medication.
 ► Documented informed consent to participate.
Key exclusion criteria
 ► Diagnosis or suspicion of other cause for Parkinsonism. Patients 
with clinical features indicating a diagnosis of progressive supra-
nuclear palsy, multiple system atrophy, drug- induced Parkinsonism, 
dystonic tremor or essential tremor will not be recruited.
 ► Patients unable to attend the clinic visits in the practically defined 
OFF medication state.
 ► Body mass index <18.5. (Exenatide is known to cause weight loss 
therefore individuals that may not tolerate further weight loss will 
not be recruited).
 ► Known abnormality on CT or MRI brain imaging considered likely to 
compromise compliance with trial protocol.
 ► Significant cognitive impairment defined by a score <21 on the 
Montreal Cognitive Assessment.
 ► Concurrent severe depression defined by a score ≥16 on the Patient 
Health Questionnaire.
 ► Prior intracerebral surgical intervention for PD. Patients who have 
previously undergone deep brain stimulation, intracerebral admin-
istration of growth factors, gene therapy or cell therapies will not 
be eligible.
 ► Previous participation in one of the following PD trials (Biogen 
SPARK trial, Prothena Pasadena trial, Sanofi Genzyme MOVES- PD 
trial, UDCA- PD UP Study or any other trial still considered to involve 
a potentially PD modifying agent). In the event of any uncertain-
ty, the chief investigator will discuss the relevance of exposure to 
any other specific trials/experimental agents with the local Principal 
Investigator before recruitment eligibility is confirmed.
 ► Participation in another clinical trial of a device, drug or surgical 
treatment within the last 30 days.
 ► Previous exposure to exenatide.
 ► Impaired renal function with creatinine clearance <50 mL/min.
 ► History of pancreatitis. Screening serum amylase value must fall 
within laboratory normal range±50%.
 ► Type 1 or type 2 diabetes mellitus.
 ► Severe gastrointestinal disease (eg, gastroparesis).
Continued
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(Edinburgh). Recruitment rates will be carefully moni-
tored throughout the trial to inform on the total number 
of sites required to ensure final recruitment milestones 
will be reached. All patient assessments will be performed 
at hospitals in the UK, after a site initiation visit has been 
performed. The trial began recruitment on 20 January 




Safety and tolerability of exenatide as indicated by 
changes in vital signs, weight, clinical laboratory measures 
and adverse events (AEs) will be recorded and monitored 
throughout. Each patient will have their pulse, blood 
pressure and weight documented at screening and at 
each follow- up visit. Exenatide is known to cause weight 
loss. Participants’ height will be recorded at screening 
to enable calculation of body mass index. At each visit, 
participants are asked to report any AEs that have 
occurred since the previous visit. AEs may also be detected 
by the study team reviewing the patient or through noti-
fication by the participant’s primary care physician. All 
AEs will be assessed by a study doctor for their severity, 
likely relationship to study drug and required action by 
a study doctor not involved in the blinded assessment 
of the patient. All SAEs will be recorded and reported 
to the sponsor regardless of relation to trial treatment. 
Any suspected unexpected serious adverse reactions will 
be reported to the sponsor immediately to allow facili-
tation of unblinding as necessary. All AEs reported will 
be reviewed by the trial management group (TMG), trial 
steering group and monitored by an Independent Data 
Monitoring Committee (IDMC). Unblinding requests 
from other clinicians responsible for a patient’s care will 
be handled by the principal investigator (PI) at each site. 
The PI at each site may also choose to unblind a partici-
pant in response to reported AEs as they are reported, if 
judged to be clinically necessary.
Primary outcome
The MDS- UPDRS part 3 motor OFF medication score is a 
widely accepted measure of the motor disability of PD. The 
scale is performed in the ON medication state and in the 
practically defined OFF medication state. This is defined as 
the score obtained in a patient who has withheld all short 
acting conventional PD medications for at least 8 hours and 
all long acting conventional PD medications for at least 36 
hours. Comparison of MDS- UPDRS part 3 motor subscore 
in the practically defined OFF medication state at 96 weeks 
between participants according to treatment allocation and 
adjusted for baseline will be the primary outcome. The 
scores for these assessments will be collected and recorded 
by trained clinical trial personnel (if possible, the same 
person will rate these assessments at each site to minimise 
inter- rater variability). With consent, these assessments will 
be video recorded as part of an MDS- UPDRS automated 
scoring sub study though the availability of these videos will 
also enable repeated independent scoring to be performed 
if there are concerns raised about data quality from a specific 
site/rater.
Secondary outcomes
Comparisons at 48 and 96 weeks between participants 
according to treatment allocation will also be performed 
for each of the secondary outcomes listed below.
MDS-UPDRS part three motor score in the practically defined OFF 
medication state
Whereas the analysis of the 96- week scores according to 
randomisation group will represent the primary outcome 
for this trial, differences emerging at 48 weeks and also 
the difference between scores at 48 weeks and 96 weeks 
will be important secondary outcomes.
MDS-UPDRS part 1, 2, 3 and 4 on medication scores
Part 3 of the MDS- UPDRS as well as the other elements (part 
1, 2 and 4) of the scale will also be evaluated in the presence 
of conventional PD medication (ON state) to evaluate any 
change in some of the NMS of PD, activities of daily living 
and the complications of chronic PD treatment.
Montreal Cognitive assessment
This scale is a validated global measure of cognitive ability. 
This will be assessed in the ON medication state.
Timed tests
Participants will be asked to perform a Sit- stand- walk 
timed test in both the OFF medication and ON medica-
tion state. The timed Sit- stand- walk test will incorporate 
Box 2 Continued
 ► Hyperlipidaemia. A lipid profile will be tested at the screening visit. 
Cholesterol or triglyceride levels greater than 2 × the upper limit of 
normal will raise suspicion of a familial or acquired hyperlipidaemia 
and will prompt referral to a relevant specialist for investigation and 
treatment.
 ► History or family history of medullary thyroid cancer. Undiagnosed 
neck lump, hoarse voice or difficulty swallowing (not attributable to 
PD diagnosis).
 ► Multiple endocrine neoplasia 2 syndrome.
 ► Hypersensitivity to any of exenatide’s excipients.
 ► Females that are pregnant or breast feeding. There are no safety 
data regarding exenatide use in pregnancy.
 ► Women of childbearing potential who are unwilling or unable to use 
an acceptable method to avoid pregnancy for the entire trial period 
and up to 3 months after the last dose of trial medication. Female 
participants who are able to become pregnant (defined as women of 
childbearing potential) will undergo a pregnancy test prior to rando-
misation and will be asked at each visit to confirm regular use of an 
effective method of contraception
 ► Participants who lack the capacity to give informed consent.
 ► Any medical or psychiatric condition or previous conventional/ex-
perimental treatment which in the investigator’s opinion compro-
mises the potential participant’s ability to participate.
UDCA, Ursodeoxycholic acid.
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time taken from seated position to stand and walk 10 
metres, turn and return to original seated position.
Unified Dyskinesia Rating Scale
This is considered to be the most useful and objective way 
of quantifying dyskinesia severity. This will be assessed in 
the ON medication state.
Patient Health Questionnaire-9
This scale allows for self- quantification of depression 
severity. This will be assessed in the ON medication state.
Non-Motor Symptom Scale
This validated scale is a tool to collect data on the 
frequency and severity of 30 NMS sometimes experienced 
by PD patients. This will be assessed in the ON medica-
tion state.
The Parkinson’s Disease Questionnaire
This is the standard disease specific measure of quality of 
life in PD comprising 39 questions. It has been extensively 
validated in previous studies.
Levodopa equivalent dose
To facilitate comparisons between patients taking 
different regimes of conventional PD medications, a set 
of conversion factors have been used to convert each of 
the commonly used PD medications to an LED of each of 
their medications can then be summed for interpatient/
intergroup comparisons.20
EQ-5D-5L
This is a simple, 5 question form and visual analogue 
scale that allows calculation of quality- adjusted life- years 
to enable health economic analyses to be performed.
The Client Service Receipt Inventory
Health and social care resource use. Self- completed 
healthcare, social care and paid/unpaid carer resource 
use questionnaire asking about primary and secondary 
care resource use relevant to Parkinson’s and impact on 
carers in the past 6 months.
Three-day Hauser diary
A 3- day Hauser diary of PD state (time- on, off, trouble-
some dyskinesia, non- troublesome dyskinesia, asleep). 
Diary data allow quantification of the amount of time 
during a 3- day period that patients spend in the varying 
states of movement ability.
Ancillary studies
There are four optional substudies linked to the main 
trial:
1. Genetics substudy: To try to identify genetic markers 
that may be associated with subtypes of PD or variation 
in treatment responsiveness.
2. Cerebrospinal Fluid (CSF) substudy: To determine 
whether any CSF changes associated with PD are in-
fluenced by exposure to exenatide. These may include 
alpha synuclein monomers or oligomers, neuroinflam-
matory markers, and exosomal contents.
3. Remote Monitoring of PD Symptoms substudy: To help 
determine whether measurement of PD symptoms us-
ing digital technology may be a more sensitive mea-
sure of change with active drug vs placebo compared 
with the MDS UPDRS 3 in the OFF and ON medica-
tion states. This will form two separate measurements 
comprising (1) home- based smartphone and (2) real- 
world gait/walking activity monitoring.21–23 This aims 
to generate precision data, providing person- specific 
distributions of outcomes and may be able to better 
delineate baseline clinical features.
4. DaTSCAN (Imaging substudy): To determine if 
change in dopamine transporter availability in the cau-
date and putaminal nuclei as measured by quantitative 
DaTSCAN signal is influenced by exposure to exenati-
de compared with placebo.
Visits
The overall progression of assessments are summarised 
in figure 1. While we expect to undertake all assessments 
in respective clinical units, provision has been made in 
line with INCLUDE guidance for the possibility of home 
visit assessments to be performed when patient specific 
situations (eg, inability to travel due to coronavirus 
restrictions, worsening ‘OFF’ state over progression of 
trial) necessitate this. We hope that this provision will 
aid overall trial retention while enhancing recruitment 
of patients from typically less well represented demo-
graphics (eg, rural geographical regions, patients lacking 
private travel facilities).
Screening visit
Written informed consent to enter and be randomised 
into the trial will be obtained from participants, after 
explanation of the aims, methods, benefits and poten-
tial hazards of the trial and before any trial- specific 
procedures are performed or any blood is taken for the 
trial. Patients will be screened using the history of their 
PD, supported by any available clinical correspondence 
according to usual standard of care.
The collection of the following scales will evaluate patient 
eligibility: Montreal Cognitive Assessment (MoCA), PHQ-9, 
as well as blood tests (full blood count, urea and electro-
lytes, creatinine, liver function tests, Haemoglobin A1c, 
C- peptide, coagulation, serum amylase, thyroid function 
tests, blood glucose, insulin and lipid profile, and a preg-
nancy test for women of childbearing potential). Tests 
can be repeated between screening and baseline visits, if 
required to confirm eligibility. Abnormalities detected that 
warrant further management for example, newly diagnosed 
diabetes will be referred for appropriate medical evaluation.
Patients recruited to the DATSCAN substudy will have 
imaging performing prior to their baseline visit.
Baseline visit and randomisation
Previously defined primary and secondary outcome 
measures will be performed in the ‘ON’ and ‘OFF’ states 
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as outlined below. Patients’ LED will be noted. Randomis-
ation to either exenatide or placebo will be administered 
using a centralised, web- based system ( www. sealedenve-
lope. com). All assessments related to sub- studies will also 
be performed prior to trial medication administration.
Assessment procedures
After the screening visit, the named site clinical staff 
member will call the participant to remind them of the 
need to stop taking their regular PD medication prior to 
their next trial visit and to attend in a fasted state (prior 
to visits 2, 4, 6, 8, 10). The MDS- UPDRS part 3 and Timed 
Walk assessments will be initially performed in the OFF 
state. This assessment in both the ‘OFF’ and ‘ON’ states 
will be performed with video recording to facilitate the 
possibility of a re- review if necessary. Remote monitoring 
assessments will be conducted at this point at selected 
sites in patients consenting to participate in this substudy. 
While waiting for medications to work, participants will 
self- complete the MDS- UPDRS parts 1, 2 and 4, Parkin-
son’s Disease Questionnaire-39, EQ- 5D- 5L and Client 
Service Receipt Inventory. The MDS- UPDRS part 3 and 
Timed Walk assessments will be repeated 1 hour after the 
participant has taken their routine medications—the ON 
medication state. After completion of the MDS- UPDRS 
and Timed Walk assessments in the ON medication state, 
each participant will be assessed using the MoCA, NMS 
scale, Unified Dyskinesia Rating Scale and PHQ-9. This 
will occur in alternate postrandomisation assessments (at 
visits 2, 4, 6, 8, 10). At selected centres participants in the 
CSF substudy will have a CSF sample taken via lumbar 
puncture. Ten weeks after the last trial medication admin-
istration, a staff member will call the participant to collect 
details of any AEs that have occurred after the partici-
pant stops taking the trial medication. Participants will 
complete the 3- day Hauser Diary prior to visits 2, 6 and 
10 and return the diary back to the research team at the 
respective study visits. At each of the visits 2, 4, 6, 8 and 
10, a blood sample will be collected and processed for 
storage for future analysis.
The DaTSCAN imaging substudy will be performed at 
the UCLH site on all consenting substudy participants; 
scans will be performed prior to visit 2 and after visit 10.
The option for performing a remote assessment will be 
provided to patients for safety monitoring visits in view of 
the coronavirus pandemic.
Intervention
Each dose of exenatide 2 mg (powder and solvent for 
prolonged release, suspension for injection, prefilled 
pen) is supplied as a single use injection pen for subcu-
taneous administration by the patient on a weekly basis. 
The placebo (inactive powder and solvent for prolonged 
release, suspension for injection, prefilled pen) is supplied 
as an identical injection pen for subcutaneous adminis-
tration by the patient on a weekly basis. The trial medi-
cation will be refrigerated and stored at 2°C–8°C. Both 
exenatide and placebo will be supplied by AstraZeneca 
as unlabelled prefilled pens in bulk and in accordance 
with Good Manufacturing Practice (GMP). Labelling, 
packaging and release of packed trial medications will be 
managed by the Sponsor’s contracted company following 
GMP. The labels will be prepared in accordance with 
GMP Annex 13 (online supplemental material 1) require-
ments for labelling and local regulatory guidelines. The 
trial medications will be released ahead of trial use.
Site trial staff will be trained on the use of exenatide 
using an online teaching video, accompanying product 
literature and the investigator’s brochure. Patients will be 
taught how to perform the subcutaneous injections by the 
clinical trial team (TT) using the online video, demon-
stration packs and written literature. They will be told 
about common adverse reactions previously reported, for 
example, nausea, vomiting, diarrhoea and weight loss by 
the clinical TT, and will be advised on the processes for 
safety reporting. In the event that exenatide injections 
will be administered by caregivers (eg, spouse), their will-
ingness to perform this will be documented and they will 
be trained using the online teaching video. It will also 
be ascertained that the caregiver either lives with the PD 
patient or confirms their willingness to meet with the PD 
participant on a weekly basis to administer the injections 
for the 96- week period of the trial.
Patients who meet eligibility criteria at the screening visit 
will be randomly assigned to receive 96 weeks of double- 
blind treatment with either exenatide or placebo (2 mg 
once weekly) in a 1:1 ratio. The first dose will be adminis-
tered by the patient in clinic following injection training 
and subsequent injections will be at home. Injections will 
be self- administered by the participants, or administered 
by their carer, into the participants’ abdomen, arm, thigh 
or buttocks every 7 days. Participants will be provided 
with a link to the injection pen training video and an 
Research Ethics Committee approved injection adminis-
tration training sheet.
Sample size
The sample size is based on the detectable effect size 
(primary outcome is the MDS- UPDRS motor subsection 
in the OFF medication state) for a two- arm (exenatide 
vs placebo) parallel- group trial design. The calculations 
assume a common SD of 13.5, and a correlation of 0.70 
between baseline and follow- up MDS- UPDRS measure-
ments. These estimates are reasonable based on data from 
the previous exenatide- PD trial.14 On this basis, 160 evalu-
able participants divided equally between the two groups 
is sufficient to detect a difference of 5.0 MDS- UPDRS part 
3 points in the OFF medication state between the two 
groups adjusting for baseline MDS- UPDRS part 3 OFF 
scores, with 90% power and at a significance level of 0.05. 
Assuming 20% attrition (withdrawal/lost to follow- up), 
200 participants will be recruited. Participants who with-
draw from the trial will not be replaced. Participants who 
withdraw from trial treatment should remain in the trial 
for the purpose of follow- up and data analysis. This effect 
size is a reasonable expectation based on the previously 
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collected pilot data and would represent a clear demon-
stration of the efficacy of exenatide on the motor severity 
of PD.
It is also anticipated that the difference in scores in 
the ON medication state will be greater at 96 weeks than 
at the earlier time points. The expected rate of change 
in PD severity in the first 5 years after PD diagnosis in 
the ON medication state is 1 MDS- UPDRS part 3 point 
per year. A predicted advantage of 2 points in ON scores 
over 96 weeks would thus equate to an advantage in 
the rate of disease progression above and beyond that 
achievable with conventional dopaminergic medication 
and would be a further clear signal that continued use of 
exenatide is consistent with not only long- term disease 
modifying effects, but even demonstration of a small 
change of 2.5 points in the MDS- UPDRS motor score 
would constitute a clinically important difference24 and 
potentially an advantage in day to day functional impair-
ment and overall improvement in quality of life in the 
short term.
Statistical analysis
A full statistical analysis plan will be written and approved 
by the TSC prior to database lock. All analyses will be 
undertaken according to a modified intention- to- treat 
principle in accordance with the randomised interven-
tion. The threshold for the analysis population will be 
participants who complete 12 weeks on treatment and for 
whom outcomes are available.
Primary outcome analysis will evaluate the impact of 
treatment allocation (exenatide or placebo) on the differ-
ence between MDS UPDRS part 3 OFF medication scores 
at 96 weeks follow- up adjusting for baseline. The analysis 
will use a mixed- model approach incorporating infor-
mation from all follow- up visits that adjusts for baseline 
Hoehn and Yahr status and the baseline raw value of each 
outcome measurement. Site will be included as a random 
effect to account for variability in outcomes between sites, 
and a random patient/subject effect will accommodate 
the correlation between repeated outcome measures on 
the same patient. A significance level of 5% will be used 
to judge significance for the primary outcome measure.
A planned secondary analysis will compare the differ-
ence in MDS- UPDRS part 3 OFF medication scores 
according to randomisation allocation at 96 weeks, with 
the scores at 48 weeks. An increase in the advantage at 96 
weeks compared with 48 weeks would be evidence that 
the active drug was slowing down disease deterioration 
rather than having symptomatic effects only. This could 
translate to a major population advantage in terms of 
reduction of morbidity and mortality.
Analyses of the remaining secondary/exploratory 
outcomes will be undertaken similarly for the difference 
between groups according to treatment allocation at 48 
and 96 weeks follow- up adjusting for baseline values of 
each outcome, and confounding factors such as LED 
differences between groups.
Further exploratory analyses will consider whether 
exenatide can be thought of as disease modifying by 
comparing slopes between groups at prespecified periods.
A sensitivity (per- protocol) analysis will be performed 
for the primary outcome measure and will only include 
those participants who completed the trial in accordance 
with the approved protocol.
Results on the primary efficacy outcome will be 
presented by stratum, according to Hoehn and Yahr stage 
(≤2.0 vs 2.5), and an interaction between Hoehn and 
Yahr and treatment will be added to the primary anal-
ysis model to investigate whether the effect of treatment 
differs according to the Hoehn and Yahr stage.
All analyses will be performed by the designated trial 
statistician.
Data management
Data will be entered in the Exenatide- PD3 database by 
delegated staff at participating sites and members of the 
Exenatide- PD3 TT at CCTU. Participants will be given a 
unique trial PIN (Exnnn). Data will be entered under the 
Personal Identification Number onto the central data-
base (InferMed’s MACRO stored on the servers based 
at UCL). The database will be password protected and 
only accessible to members of the Exenatide- PD3 TT and 
external regulators if requested. Video recordings of the 
MDS- UPDRS will be uploaded onto a secure cloud held 
by Machine Medicines Technologies (MMT) and used for 
quality control purposes. Appropriate contractual agree-
ments covering data protection are in place with MMT. 
All data storage will adhere to GDPR and the Data Protec-
tion Act 2018.
An IDMC will be convened including at least three indi-
viduals independent from the TT and sponsor who have 
experience in the conduct of clinical trials for PD. The 
IDMC will review the trial results and make a recommen-
dation to the TSC regarding continuation/stopping of 
the trial based on safety data. A statistician independent 
of the Exenatide- PD3 TT at CCTU will generate summa-
ries of accumulating trial data for the IDMC to review.
UCL is the trial sponsor and has delegated the duties 
as sponsor to CCTU via a signed letter of delegation. The 
trial sponsor will take on responsibility for securing the 
arrangements to initiate, manage and finance the trial. 
Trial oversight is intended to preserve the integrity of the 
trial by independently verifying processes and prompting 
corrective action where necessary. In multicentre trials 
this oversight is considered and described both overall 
and for each recruiting centre by exploring the trial 
dataset or performing site visits. The TT will assist with 
developing the design, coordination and day- to- day oper-
ational issues in the management of the trial, including 
budget management. The TMG will assist with developing 
the design, co- ordination and strategic management of 
the trial. The independent TSC is the independent group 
responsible for oversight of the trial in order to safeguard 
the interests of trial participants. The TSC will provide 
advice to the chief investigator, CCTU, the funder and 
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sponsor on all aspects of the trial through its indepen-
dent Chair. The IDMC is the only oversight body that has 
access to unblinded accumulating comparative data. The 
IDMC will be responsible for safeguarding the interests 
of trial participants, monitoring the accumulating data 
and making recommendations to the TSC on whether 
the trial should continue as planned. The membership, 
frequency of meetings, activity (including trial conduct 
and data review) and authority of each committee will be 
covered in their respective terms of reference.
ETHICS AND DISSEMINATION
The trial protocol, all informed consent forms and any 
material to be given to the prospective participant have 
received REC (initial date of approval 15/10/2019, 
REC reference no.19/SC/0447), and other regulatory 
approvals (EudraCT 2018-003028-35). Further, the trial 
was registered in  clinicatrials. gov NCT004232969 and in 
ISRCTN (reference 14552789). Subsequent amendments 
to these documents will be submitted for further approval. 
The same/amended documents will be submitted for 
additional local permissions at each clinical site.
This is a Clinical Trial of an IMP as defined by the EU 
Directive 2001/20/EC. Therefore, a clinical trial authori-
sation is required in the UK and the trial protocol will 
therefore be submitted to the UK regulatory authority 
(MHRA). The progress of the trial, safety issues and 
reports, including expedited reporting will be reported to 
the MHRA as required. The protocol, PIS and informed 
consent forms on local headed paper, the REC/HRA 
and MHRA approvals, schedules of funding and activity 
(and other trial documentation as needed) have been 
submitted to the relevant NHS Trust Research & Devel-
opment department of each participating site or to other 
local departments for approval.
Participants will be provided with a PIS and given time 
to read it fully. Following a discussion with a medical qual-
ified investigator or suitable trained and authorised dele-
gate, any questions will be satisfactorily answered and if 
the participant is willing to participate, written informed 
consent will be obtained (online supplemental material 
2). During the consent process, it will be emphasised that 
the participant is free to refuse to participate in all or any 
aspect of the trial, at any time and for any reason, without 
affecting their treatment. The risk/benefit profile of the 
trial will be regularly monitored. Consent will be resought 
if new information becomes available that affects the 
participant’s consent in any way.
The rights of the participant to refuse to participate 
in the trial without giving a reason will be respected and 
after the participant has entered the trial, the clinician 
remains free to give alternative treatment to that specified 
in the protocol, at any stage. The participant remains free 
to change their mind at any time about the protocol treat-
ment and follow- up without giving a reason and without 
prejudicing their further treatment. All participants will 
be made aware of the known adverse reactions.
DISCUSSION
A parallel group design with a washout period has been 
used previously in the evaluation of potential neuro-
protective agents.25 26 and this was chosen as the design 
for the previous phase 2 trial. This design is subject to 
possible long duration symptomatic effects and a lengthy 
washout period potentially impacts on patient retention 
and cannot necessarily distinguish a true neuroprotec-
tive effect from a symptomatic effect (in view of pres-
ervation of healthy behaviours with long term impacts 
such as exercise).27 An alternative approach which we 
have adopted here is a ‘long- term simple’ design, with 
longer- term follow- up to look for a cumulative advantage 
emerging with prolonged treatment exposure, given the 
natural history of PD being that of progressive accumu-
lation of motor and non- motor disability.28 This design 
helps build on the previous successful clinical trials of 
exenatide which have introduced a novel, cost effective 
way of evaluating the potential for disease modifying 
drugs in PD by recruiting patients already in receipt 
of conventional dopaminergic treatment, rather than 
restricting recruitment to incident cases yet to receive 
dopaminergic treatment. Using this approach, we have 
successfully demonstrated the potential for rapid recruit-
ment, and improved retention of participants enabling 
more complete follow- up, and a statistically significant 
advantage in motor scores in people randomised to exen-
atide over a 48- week period of treatment exposure. We 
have considered that an exposure period of 96 weeks 
would allow exploration of long- term effects of exenatide 
exposure, while being the maximum period that partici-
pants would be willing to accept being allocated placebo. 
Furthermore, this will provide the opportunity to eval-
uate whether the 48- week data previously published can 
be replicated and whether effects at 96 weeks are similar 
to or greater than those seen at 48 weeks and other earlier 
time points.
Many trials have attempted to evaluate the potential 
for disease modification using drugs with broad mech-
anisms of action. The majority have either failed to 
demonstrate clinical efficacy or provided inconclusive 
results. Some pertinent reasons for this are a failure of 
the investigated agent to reach and engage its target and 
lack of objective measures of true clinical disease progres-
sion. Clinical endpoints such as the MDS- UPDRS scale 
are necessary to ultimately confirm relevance; however, 
these scales lack sensitivity for capturing disease modifi-
cation unless very long term follow- up data are collected. 
While our approach of following patients for 2 years in 
this trial will partially mitigate some of this, the addition 
and to an extent validation of more detailed approaches 
through a number of sub studies (imaging, CSF anal-
ysis for target engagement and drug levels, and device 
assisted measurements of real- life motor function) could 
ultimately provide more holistic and definitive metrics 
for determining if exenatide does in fact deliver disease 
modification in PD. This more comprehensive approach 
to approaching assessments and the consistent signal of 
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benefit noted in two earlier trials provide grounds for 
optimism that the primary outcome will be achievable. 
The study opened to recruitment in January 2020 and we 
expect completion of study analysis by Q3 2024.
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